No profile data available.
AbCellera Biologics Inc. (ABCL) is a healthcare company in the medication development research industry, based in Vancouver, Canada, with about 562 full-time employees.
It reported revenue of $75.13 million for fiscal year 2025, up 160.6% from fiscal year 2024, and net income of -$146.41 million. Its market capitalization was $3.90 billion as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
AbCellera Biologics reported $75.13 million in revenue for fiscal year 2025, up 160.6% from $28.83 million in fiscal year 2024.
$3.90 billion as of October 8, 2026.
Listed companies of a similar size in the same industry (medication development research) include Tango Therapeutics, Inc. (TNGX), Recursion Pharmaceuticals, Inc. (RXRX), Absci Corporation (ABSI), Evotec SE (EVO).